Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412943 · ClinicalTrials.gov registry record · Phase 1
Pappalysin 2 (PAPP-A2) Enzyme Replacement
A Phase 1 study of Short Stature, Idiopathic, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT02412943: Completed Phase 1 study of Short Stature, Idiopathic, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02412943 is a Phase 1 study of Short Stature, Idiopathic that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02412943, a Phase 1 study of Short Stature, Idiopathic, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the transfusion of fresh frozen plasma containing the enzyme PAPP-A2 into the a female adult. This female adult has a mutated version of PAPP-A2 that prevents the unbinding of IGF-1 from IGF binding proteins. The investigator's hypothesize that transfusion of plasma with donor PAPP-A2 will lead to the unbinding of IGF-1 from its binding proteins and that they will be able to measure free IGF-1 in the blood of this female adult.
Primary Outcome
Decrease in either total IGF-1 or IGFBP-3 of 20% or greater as a clinically meaningful decrease in levels
Conditions Studied
Interventions
- OTHER Fresh Frozen Plasma
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02412943 record still lists
NCT02412943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Short Stature, Idiopathic appearing as the primary indexed condition, and to 1 intervention - of which Fresh Frozen Plasma is the first listed.
NCT02412943 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02412943 about?
NCT02412943 is a clinical study titled "Pappalysin 2 (PAPP-A2) Enzyme Replacement". This study evaluates the transfusion of fresh frozen plasma containing the enzyme PAPP-A2 into the a female adult. This female adult has a mutated version of PAPP-A2 that prevents the unbinding of IGF-1 from IGF binding proteins. The investigator's hypothesize that transfusion of plasma with donor P...
What is the current status of trial NCT02412943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-04. Estimated completion is 2015-05.
What conditions does trial NCT02412943 study?
This clinical trial studies the following conditions: Short Stature, Idiopathic.
What interventions are being tested in trial NCT02412943?
The interventions under investigation include: Fresh Frozen Plasma (OTHER).
Who is sponsoring clinical trial NCT02412943?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02412943 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02412943's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia